Longeveron Inc
LGVN1.700USD
+0.065+3.98%
Market hours （ET）Quotes delayed by 15 min
25.43MMarket Cap
LossP/E TTM
More Details of Longeveron Inc Company
Longeveron Inc. is a clinical-stage biotechnology company. The Company is focused on developing cellular therapies for specific aging-related and life-threatening conditions. The Company's lead investigational product is the LOMECEL-B cell-based therapy product (Lomecel-B), which is derived from culture-expanded medicinal signaling cells (MSCs) that are sourced from bone marrow of young healthy adult donors. The Company is primarily focused on three pipeline indications, which include Hypoplastic Left Heart Syndrome (HLHS), Alzheimer’s disease (AD) and Aging-related Frailty. Its Lomecel-B has multiple mechanisms of action encompassing pro-vascular, pro-regenerative, anti- inflammatory, and tissue repair and healing effects with potential applications across a spectrum of disease areas. The Company has bone marrow supply contracts in with two suppliers: the Oklahoma Blood Institute and Vista Health Research.
Company Info
Ticker SymbolLGVN
Company nameLongeveron Inc
IPO dateFeb 12, 2021
CEOMr. Wa'el Hashad
Number of employees25
Security typeOrdinary Share
Fiscal year-endFeb 12
Address1951 NW 7th Ave
CityMIAMI
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code33136
Phone13053027158
Websitehttps://www.longeveron.com/
Ticker SymbolLGVN
IPO dateFeb 12, 2021
CEOMr. Wa'el Hashad
Company Executives
Name
Name/Position
Position
Shareholding
Change
Dr. Joshua M. Hare, M.D.
Dr. Joshua M. Hare, M.D.
Chairman of the Board, Co-Founder, Chief Science Officer
Chairman of the Board, Co-Founder, Chief Science Officer
253.07K
-2.03%
Ms. Lisa Locklear
Ms. Lisa Locklear
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
152.53K
+163.15%
Dr. Nataliya Agafonova, M.D.
Dr. Nataliya Agafonova, M.D.
Chief Medical Officer
Chief Medical Officer
152.03K
+164.57%
Mr. Devin Blass
Mr. Devin Blass
Chief Technology Officer, Senior Vice President - Chemistry, Manufacturing, and Controls
Chief Technology Officer, Senior Vice President - Chemistry, Manufacturing, and Controls
110.15K
+763.93%
Ms. Ursula Ungaro
Ms. Ursula Ungaro
Independent Director
Independent Director
35.55K
+91.64%
Mr. Khoso Baluch
Mr. Khoso Baluch
Independent Director
Independent Director
29.59K
+135.01%
Mr. Richard N. Kender
Mr. Richard N. Kender
Independent Director
Independent Director
22.33K
+318.71%
Mr. Roger Joseph Hajjar
Mr. Roger Joseph Hajjar
Independent Director
Independent Director
21.00K
+425.00%
Ms. Neha Motwani
Ms. Neha Motwani
Independent Director
Independent Director
21.00K
+425.00%
Mr. Rock Soffer
Mr. Rock Soffer
Director
Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Joshua M. Hare, M.D.
Dr. Joshua M. Hare, M.D.
Chairman of the Board, Co-Founder, Chief Science Officer
Chairman of the Board, Co-Founder, Chief Science Officer
253.07K
-2.03%
Ms. Lisa Locklear
Ms. Lisa Locklear
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
152.53K
+163.15%
Dr. Nataliya Agafonova, M.D.
Dr. Nataliya Agafonova, M.D.
Chief Medical Officer
Chief Medical Officer
152.03K
+164.57%
Mr. Devin Blass
Mr. Devin Blass
Chief Technology Officer, Senior Vice President - Chemistry, Manufacturing, and Controls
Chief Technology Officer, Senior Vice President - Chemistry, Manufacturing, and Controls
110.15K
+763.93%
Ms. Ursula Ungaro
Ms. Ursula Ungaro
Independent Director
Independent Director
35.55K
+91.64%
Mr. Khoso Baluch
Mr. Khoso Baluch
Independent Director
Independent Director
29.59K
+135.01%
Revenue Breakdown
Currency: USDUpdated: Sun, Jul 6
Currency: USDUpdated: Sun, Jul 6
FY2025Q1
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
By BusinessUSD
Name
Revenue
Proportion
Clinical trial revenue
259.00K
67.98%
Contract manufacturing lease revenue
116.00K
30.45%
Contract manufacturing
6.00K
1.57%
No Data
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Clinical trial revenue
259.00K
67.98%
Contract manufacturing lease revenue
116.00K
30.45%
Contract manufacturing
6.00K
1.57%
Shareholding Stats
Updated: Fri, Aug 1
Updated: Fri, Aug 1
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Armistice Capital LLC
5.00%
Lehr (Paul T)
2.44%
Hashad (Mohamed Wa'el Ahmed)
2.30%
Hare (Joshua M)
1.87%
Soffer (Rock J)
1.33%
Other
87.06%
Shareholders
Shareholders
Proportion
Armistice Capital LLC
5.00%
Lehr (Paul T)
2.44%
Hashad (Mohamed Wa'el Ahmed)
2.30%
Hare (Joshua M)
1.87%
Soffer (Rock J)
1.33%
Other
87.06%
Shareholder Types
Shareholders
Proportion
Individual Investor
12.30%
Hedge Fund
5.00%
Investment Advisor
2.18%
Investment Advisor/Hedge Fund
1.49%
Research Firm
0.11%
Other
78.93%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
73
2.17M
16.04%
+290.03K
2025Q1
73
2.14M
15.82%
-119.71K
2024Q4
73
2.53M
18.80%
+652.31K
2024Q3
67
2.33M
17.58%
+1.38M
2024Q2
67
924.88K
16.16%
+194.99K
2024Q1
64
168.05K
15.95%
-258.83K
2023Q4
68
363.47K
37.19%
+110.22K
2023Q3
73
198.13K
31.46%
-72.89K
2023Q2
70
193.49K
31.19%
-39.22K
2023Q1
64
155.94K
27.45%
-36.93K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Armistice Capital LLC
676.23K
5%
+676.23K
--
Sep 30, 2024
Lehr (Paul T)
229.86K
1.7%
+98.89K
+75.50%
Jun 23, 2025
Hashad (Mohamed Wa'el Ahmed)
144.05K
1.06%
-10.99K
-7.09%
Apr 21, 2025
Hare (Joshua M)
253.07K
1.87%
-5.25K
-2.03%
May 16, 2025
Soffer (Rock J)
162.52K
1.2%
-23.00K
-12.40%
May 30, 2025
Locklear (Lisa)
57.96K
0.43%
-6.21K
-9.68%
Apr 21, 2025
Agafonova (Nataliya)
57.46K
0.42%
-7.56K
-11.63%
Apr 21, 2025
The Vanguard Group, Inc.
144.27K
1.07%
--
--
Mar 31, 2025
Geode Capital Management, L.L.C.
140.73K
1.04%
+7.13K
+5.33%
Mar 31, 2025
Blass (Devin)
12.75K
0.09%
+12.75K
--
Apr 21, 2025
View more
Related ETFs
Updated: Sat, Aug 2
Updated: Sat, Aug 2
Name
Proportion
iShares Micro-Cap ETF
0%
iShares Micro-Cap ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Mar 19, 2024
Merger
10<1
Mar 19, 2024
Merger
10<1
Mar 19, 2024
Merger
10<1
Mar 19, 2024
Merger
10<1
Date
Type
Ratio
Mar 19, 2024
Merger
10<1
Mar 19, 2024
Merger
10<1
Mar 19, 2024
Merger
10<1
Mar 19, 2024
Merger
10<1
